Major depressive disorder, recurrent, moderate
Methodology & AI Transparency ⓘ
Major depressive disorder, recurrent, moderate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Major depressive disorder, recurrent, moderate (F33.1; Depression, Bipolar & Mood Disorders) utilize sleep-wake rhythm assessment [Major depressive disorder, recurrent, moderate F33.1] and objective PHQ-9 Symptom Severity in Major depressive disorder, recurrent, moderate (F33.1: Score) targets (< 4 (clinical remission) (F33.1)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code F33.1 categorizes Major depressive disorder, recurrent, moderate under Depression, Bipolar & Mood Disorders.
- 3 Typical cash cost range: Differential triage of Major depressive disorder, recurrent, moderate (F33.1) utilizes sleep-wake rhythm assessment [Major depressive disorder, recurrent, moderate F33.1].
- 4 Top reported side effects / signs: Follow-up benchmark in Major depressive disorder, recurrent, moderate: maintaining PHQ-9 Symptom Severity in Major depressive disorder, recurrent, moderate (F33.1: Score) within < 4 (clinical remission) (F33.1).
Ask our AI Specialists anything about Major depressive disorder, recurrent, moderate
What Is Major depressive disorder, recurrent, moderate?
Physicians managing Major depressive disorder, recurrent, moderate (F33.1; Depression, Bipolar & Mood Disorders) utilize sleep-wake rhythm assessment [Major depressive disorder, recurrent, moderate F33.1] and objective PHQ-9 Symptom Severity in Major depressive disorder, recurrent, moderate (F33.1: Score) targets (< 4 (clinical remission) (F33.1)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Major depressive disorder, recurrent, moderate (F33.1) features norepinephrine [Major depressive disorder, recurrent, moderate F33.1]. therapeutic stabilization in depression & mood is verified against TSH & Free in Major depressive disorder, recurrent, moderate (F33.1: T4 Rule-Out).
Common Symptoms & Clinical Signs
- • Presentation of Major depressive disorder, recurrent, moderate (F33.1): loss of interest in Major depressive disorder, recurrent, moderate (F33.1: or pleasure in)
- • Secondary Major depressive disorder, recurrent, moderate clinical sign: persistent low mood, in Major depressive disorder, recurrent, moderate (F33.1: emotional flatness, or)
- • Symptom flares in Major depressive disorder, recurrent, moderate correlating with PHQ-9 Symptom Severity in Major depressive disorder, recurrent, moderate (F33.1: Score) deviation outside < 4 (clinical remission) (F33.1)
- • Functional depression & mood impact requiring sleep-wake rhythm assessment [Major depressive disorder, recurrent, moderate F33.1] evaluation (F33.1)
Major depressive disorder, recurrent, moderate Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F33.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Major depressive disorder, recurrent, moderate (F33.1: Score) | < 4 (clinical remission) (F33.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Major depressive disorder, recurrent, moderate (F33.1: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F33.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Major depressive disorder, recurrent, moderate (F33.1: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F33.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Major depressive disorder, recurrent, moderate
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Hemin Panhematin • RxCUI 1926452 | FDA Prescription Therapeutic Agent | 81% | $1.0300 | $ 50.22 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Major depressive disorder, recurrent, moderate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake: What a 10,039-Participant Study Found Higher doses of SSRIs appear slightly more effective in depression. The American journal of psychiatry • 2016-02-01 • Meta-Analysis | N = 10,039 | 99/100 | PMID 26552940 ↗ |
| New Insights on Pharmacological and non-pharmacological treatments for depression in: What a 10,991-Participant Study Found Herbal medicine and mirtazapine had no significant difference in overall risk of side effects compared with placebo. Psychiatry research • 2019-11-15 • Meta-Analysis | N = 10,991 | 99/100 | PMID 31627074 ↗ |
| New Insights on Antidepressants for the treatment of adults with depression in the maintenance: What a 9,384-Participant Study Found Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. Molecular psychiatry • 2023-01-15 • Meta-Analysis | N = 9,384 | 99/100 | PMID 36253442 ↗ |
| New Insights on Modeling the efficacy of a novel antidepressant zuranolone for: What a 8,735-Participant Study Found Primary side effects related to zuranolone included somnolence, headache, dizziness, and sedation, with no severe safety signals observed. Journal of affective disorders • 2026-01-01 • Meta-Analysis | N = 8,735 | 99/100 | PMID 40876640 ↗ |
| New Insights on Major outcomes in high-risk hypertensive patients randomized to: What a 9,048-Participant Study Found Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. JAMA • 2002-12-18 • Randomized Controlled Trial | N = 9,048 | 96/100 | PMID 12479763 ↗ |
Major depressive disorder, recurrent, moderate Patient Community & “People Like Me” Threads
Filter Major depressive disorder, recurrent, moderate community threads and patient logs by age, biological sex, dosage, and treatment duration.